Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Page Path

HOME
ARTICLE CATEGORY
Editorial

Editorial

The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(1):99-101. Published online October 27, 2022

DOI: https://doi.org/10.3350/cmh.2022.0321

View: 4359 Download: 90 Web of Science: 3 Crossref: 4

Surveillance for hepatocellular carcinoma: It is time to move forward

Bo Hyun Kim, Yuri Cho, Joong-Won Park

Clin Mol Hepatol. 2022;28(4):810-813. Published online September 6, 2022

DOI: https://doi.org/10.3350/cmh.2022.0257

View: 4023 Download: 97 Web of Science: 5 Crossref: 5

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):806-809. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0208

View: 3395 Download: 73

Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations

Soon Sun Kim, Jae Youn Cheong

Clin Mol Hepatol. 2022;28(4):802-805. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0249

View: 3693 Download: 83 Web of Science: 3 Crossref: 4

Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults

Byoung Seok Ye

Clin Mol Hepatol. 2022;28(3):481-482. Published online May 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0097

View: 3621 Download: 85 Web of Science: 1 Crossref: 2

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease

Seonghwan Hwang, Won Kim

Clin Mol Hepatol. 2022;28(3):478-480. Published online June 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0143

View: 3947 Download: 95

Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?

Qian Jin, Rui-Xu Yang, Jian-Gao Fan

Clin Mol Hepatol. 2022;28(3):473-477. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0155

View: 4587 Download: 109 Web of Science: 2 Crossref: 2

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles

Hung-Yao Lin, Tai-Chung Tseng

Clin Mol Hepatol. 2022;28(2):181-182. Published online February 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0028

View: 5252 Download: 124 Web of Science: 6 Crossref: 5

Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis

Takumi Kawaguchi, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):177-180. Published online August 26, 2021

DOI: https://doi.org/10.3350/cmh.2021.0246

View: 5922 Download: 185 Web of Science: 4 Crossref: 4

Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still open

Bo Hyun Kim

Clin Mol Hepatol. 2022;28(2):174-176. Published online January 26, 2022

DOI: https://doi.org/10.3350/cmh.2021.0400

View: 4652 Download: 119 Web of Science: 3 Crossref: 3

Non-alcoholic fatty liver disease in pregnancy, paving the way for adverse pregnancy outcome risk assessment

Ja-Young Kwon

Clin Mol Hepatol. 2022;28(1):50-51. Published online November 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0359

View: 4830 Download: 108

Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?

Seung Mi Lee, Won Kim

Clin Mol Hepatol. 2022;28(1):47-49. Published online November 30, 2021

DOI: https://doi.org/10.3350/cmh.2021.0338

View: 5002 Download: 117 Web of Science: 4 Crossref: 5

Can hepatocellular carcinoma recurrence be prevented after liver transplantation?

Jong Man Kim

Clin Mol Hepatol. 2021;27(4):562-563. Published online September 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0276

View: 4720 Download: 137 Web of Science: 3 Crossref: 3

Microwave thermosphere versus radiofrequency ablation for hepatocellular carcinoma: Are we approaching the time to end the debate?

Man-Deuk Kim

Clin Mol Hepatol. 2021;27(4):560-561. Published online September 8, 2021

DOI: https://doi.org/10.3350/cmh.2021.0279

View: 4546 Download: 136 Web of Science: 1 Crossref: 1

Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2021;27(3):448-450. Published online June 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0130

View: 4980 Download: 129 Web of Science: 2 Crossref: 1

An analysis of polygenic risk scores for non-alcoholic fatty liver disease

Dae Won Jun

Clin Mol Hepatol. 2021;27(3):446-447. Published online May 21, 2021

DOI: https://doi.org/10.3350/cmh.2021.0133

View: 5346 Download: 162 Web of Science: 5 Crossref: 6

Another oral antiviral treatment, but still far away from hepatitis B virus cure

Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(2):281-282. Published online March 10, 2021

DOI: https://doi.org/10.3350/cmh.2021.0072

View: 4459 Download: 103 Web of Science: 5 Crossref: 5

Biopsy or cytology for diagnosing hepatic focal lesions?

Haeryoung Kim

Clin Mol Hepatol. 2021;27(2):278-280. Published online March 4, 2021

DOI: https://doi.org/10.3350/cmh.2021.0031

View: 4376 Download: 87 Web of Science: 2 Crossref: 2

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact

Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2021;27(2):273-277. Published online February 1, 2021

DOI: https://doi.org/10.3350/cmh.2021.0019

View: 5482 Download: 142 Web of Science: 6 Crossref: 6

A need for patient-centered care in managing patients with liver cirrhosis

Eileen L. Yoon

Clin Mol Hepatol. 2021;27(2):270-272. Published online January 27, 2021

DOI: https://doi.org/10.3350/cmh.2021.0001

View: 4366 Download: 121 Web of Science: 2 Crossref: 2

Old hepatitis B virus never dies: It just hides itself within the host genome

Jeong-Hoon Lee

Clin Mol Hepatol. 2021;27(1):107-109. Published online December 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0324

View: 4532 Download: 120 Web of Science: 4 Crossref: 3

Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma

Jun Won Kim, Ik Jae Lee

Clin Mol Hepatol. 2021;27(1):103-106. Published online December 14, 2020

DOI: https://doi.org/10.3350/cmh.2020.0297

View: 4839 Download: 102 Web of Science: 1 Crossref: 1

Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care

Seong Hee Kang, Moon Young Kim

Clin Mol Hepatol. 2021;27(1):100-102. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0312

View: 5414 Download: 83 Web of Science: 6 Crossref: 6

Elimination of hepatitis C: What would be the practical approach?

Hyung Joon Yim

Clin Mol Hepatol. 2021;27(1):97-99. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0304

View: 6602 Download: 125 Web of Science: 2 Crossref: 2

Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever

Marta Tonon, Salvatore Piano

Clin Mol Hepatol. 2021;27(1):94-96. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0305

View: 5432 Download: 147 Web of Science: 8 Crossref: 8

The cutoff of transient elastography for the evaluation of portal hypertension should be different according to the etiology?

Beom Kyung Kim

Clin Mol Hepatol. 2021;27(1):91-93. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0311

View: 4516 Download: 92 Web of Science: 5 Crossref: 6

Metabolic disease as a risk of hepatocellular carcinoma

Naoshi Nishida

Clin Mol Hepatol. 2021;27(1):87-90. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0302

View: 5834 Download: 119 Web of Science: 15 Crossref: 17

Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try

Tian-Yi Ren, Xiao-Yan Li, Jian-Gao Fan

Clin Mol Hepatol. 2021;27(1):83-86. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0298

View: 5870 Download: 170 Web of Science: 1 Crossref: 1

Drug-drug interactions with direct-acting antivirals — less is more

Grace Lai-Hung Wong

Clin Mol Hepatol. 2021;27(1):81-82. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0278

View: 4529 Download: 104 Web of Science: 1 Crossref: 1

More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis

Paul Kwo, Deepti Dronamraju

Clin Mol Hepatol. 2020;26(4):489-491. Published online September 24, 2020

DOI: https://doi.org/10.3350/cmh.2020.0228

View: 4760 Download: 77 Web of Science: 1 Crossref: 1

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Video abstract

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation
Impact Factor

14.0
First decision

07 Days

Publication after acceptance

04 Days

*Last 12 months

MOST VIEWED MOST CITED

MOST VIEWED (Last 6 months)

Viewed By 6974	MAFLD: How is it different from NAFLD?
Viewed By 6225	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5317	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5150	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4664	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

MOST CITED (2023-2025)

Cited By 298	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 266	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 170	MAFLD: How is it different from NAFLD?
Cited By 92	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 88	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: cmh_journal@ijpnc.com

Copyright © The Korean Association for the Study of the Liver.

COUNTER

TODAY : 1561

TOTAL : 2551281